APA (7th ed.) Citation

Tohda, Y., Fujimura, M., Taniguchi, H., Takagi, K., Igarashi, T., Yasuhara, H., . . . Nakajima, S. (2002). Leukotriene receptor antagonist, montelukast, can reduce the need for inhaled steroid while maintaining the clinical stability of asthmatic patients. Clinical & Experimental Allergy, 32(8), 1180. https://doi.org/10.1046/j.1365-2745.2002.01440.x

Chicago Style (17th ed.) Citation

Tohda, Y., M. Fujimura, H. Taniguchi, K. Takagi, T. Igarashi, H. Yasuhara, K. Takahashi, and S. Nakajima. "Leukotriene Receptor Antagonist, Montelukast, Can Reduce the Need for Inhaled Steroid While Maintaining the Clinical Stability of Asthmatic Patients." Clinical & Experimental Allergy 32, no. 8 (2002): 1180. https://doi.org/10.1046/j.1365-2745.2002.01440.x.

MLA (9th ed.) Citation

Tohda, Y., et al. "Leukotriene Receptor Antagonist, Montelukast, Can Reduce the Need for Inhaled Steroid While Maintaining the Clinical Stability of Asthmatic Patients." Clinical & Experimental Allergy, vol. 32, no. 8, 2002, p. 1180, https://doi.org/10.1046/j.1365-2745.2002.01440.x.